Showing results (351-360 of 427) with videos related to
Sort By:
Pageof 43
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2020
MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I TrialDebashis Sarker, Ruth Plummer, Tim Meyer, et al.European Journal of Cancer (Oxford, England : 1990)|September 23, 2022
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real studyClaudia Angela Maria Fulgenzi, Jaekyung Cheon, Antonio D'Alessio, et al.Clinical Lung Cancer|February 28, 2025
Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (≥50%) PatientsAdriana P C Barrichello, Arielle Elkrief, Biagio Ricciuti, et al.Cancer Letters|June 5, 2024
Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort studyKylie Fletcher, Alessio Cortellini, Teja Ganta, et al.Clinical Genitourinary Cancer|July 6, 2023
Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" ExperienceDimitra Rafailia Bakaloudi, Rafee Talukder, Genevieve Ihsiu Lin, et al.Cancers|January 11, 2022
The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular CarcinomaAmbreen Muhammed, Claudia Angela Maria Fulgenzi, Sirish Dharmapuri, et al.Journal for Immunotherapy of Cancer|October 6, 2025
Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumabBernhard Scheiner, Pasquale Lombardi, Antonio D'Alessio, et al.Journal for Immunotherapy of Cancer|November 6, 2020
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practiceAlessio Cortellini, Marco Tucci, Vincenzo Adamo, et al.Journal of Hepatology|October 14, 2021
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY scoreBernhard Scheiner, Katharina Pomej, Martha M Kirstein, et al.JHEP Reports : Innovation in Hepatology|January 29, 2025
Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumabMeng Wu, Claudia A M Fulgenzi, Antonio D'Alessio, et al.Pageof 43